aSIRTing Control over Cancer Stem Cells

Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.
Cancer cell (Impact Factor: 23.52). 02/2012; 21(2):140-2. DOI: 10.1016/j.ccr.2012.01.014
Source: PubMed


Cancer stem cells lie at the root of chronic myelogenous leukemia (CML) and mediate its continued growth. Their resistance to current therapies results in an inability to eradicate the disease. In this issue of Cancer Cell, Li et al. identify SIRT1 as a new target for eliminating CML cancer stem cells.

Full-text preview

Available from:
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Cancer stem cells (CSCs) are a high profile drug target for cancer therapeutics due to their indispensable role in cancer progression, maintenance and therapeutic resistance. Restoring wild-type (WT) p53 function is an attractive new therapeutic approach for the treatment of cancer due to the well-described powerful tumor suppressor function of p53. As emerging evidence intimately links p53 and stem cell biology, this approach also provides an opportunity to target CSCs. Areas covered: This review covers the therapeutic approaches to restore the function of WT p53, cancer and normal stem cell biology in relation to p53 and the downstream effects of p53 on CSCs. Expert opinion: The restoration of WT p53 function by targeting p53 directly, its interacting proteins or its family members holds promise as a new class of cancer therapies. This review examines the impact that such therapies may have on normal and CSCs based on the current evidence linking p53 signaling with these populations.
    Full-text · Article · Nov 2012 · Expert Opinion on Therapeutic Targets
  • [Show abstract] [Hide abstract]
    ABSTRACT: Prostate cancer is the most common cancer diagnosis and the second deadliest non-cutaneous cancer in men in the western world. Despite the advancement of new therapies, survival rates remain tightly correlated to the stage in which a patient is diagnosed. The heterogeneous nature of tumor and their variable response to therapies is now being attributed to tumor-initiating cells or cancer stem cells. The cancer stem cell hypothesis suggests that cancer initiates from a specifi c subset of tumor cells that possess “stemlike” properties. Over the past several decades, the use of natural or synthetic agents such as vitamins, foods, or spices has been shown to correlate with lower incidences of cancer. Many of these chemopreventive agents have now been reported to cause differentiation of cancer stem cells and suppress their proliferation, thereby making them more amenable to conventional therapies. This chapter will discuss the use of chemoprevention to target cancer stem cells and how these approaches can be applied to prostate cancer.
    No preview · Chapter · Jan 2013
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aging is a degenerative process resulting in compromised tissue maintenance and increased susceptibility to diseases, such as cancer. Recent advancements support the notion that aging is a highly regulated process governed by evolutionarily conserved pathways. In mammals, tissue-specific adult stem cells (ASCs) persist throughout the lifetime to maintain and repair tissues. While reduced ASC self-renewal is thought to contribute to compromised tissue maintenance, increased self-renewal of cancer stem cells (CSCs) may lead to tumorigenesis. It is speculated that genetic regulators of aging, such as sirtuins, are likely to impinge upon the ASC compartments to regulate tissue maintenance and tumorigenesis. In this review, we discuss the emerging evidence linking sirtuins to normal and malignant ASC self-renewal, tissue maintenance, and tumorigenesis.
    Preview · Article · Mar 2013 · Genes & cancer
Show more